GlaxoSmithKline Sales Down in Q3 against Good Underlying Momentum in the Business

LONDON, October 31, 2012 /PRNewswire/ –

GlaxoSmithKline released third quarter results today with Finance Director Simon
Dingemans saying the pharma group was on course to deliver growth in Q4 and sales “broadly
in line” with the previous year.

In a video interview Mr Dingemans said while factors such as costs from disposals and
weak European sales had added to a difficult quarter where total sales were down 5%,
performances from promoted and new products plus R&D developments meant shareholders saw
dividends up 6% year-on-year.

“I think we’re pleased with the progress that the growth drivers and the core
strategic businesses are making and I think overall that leaves us feeling that we have
good momentum going into the fourth quarter.”

The interview and transcript are available now on

http://www.cantos.com/company/GlaxoSmithKline.

MerchantCantos produces in-depth interviews, documentaries and webcasts with senior
company executives. If you would like to contact us, please email
prnsupport@merchantcantos.com or phone +44-207-936-1352.

SOURCE GlaxoSmithKline